RxDoctor Payments Data

Mariam Khan, MD

Rheumatology · Elmhurst, ILNPI 1225317464

Payments from drug & device makers

$1,526in general payments, 2019–2025

Across 52 payments — averaging $29.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$442
  • Amgen$429
  • UCB, Inc.$185
  • Lilly USA, LLC$107
  • Boehringer Ingelheim$85
  • Pfizer$77
  • plus $201 from 5 others

What the payments were for

  • Food & beverage$1,44695%
  • Education$805%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie16$442
Amgen10$429
UCB, Inc.7$185
Lilly USA, LLC5$107
Boehringer Ingelheim1$85
Pfizer4$77
AstraZeneca(2 entities)4$63
GSK2$46
Sobi, Inc1$41
E.r. Squibb & Sons, L.L.C.1$29
Novartis1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,526 in reported general payments places this provider in the 50th percentile of 287 rheumatology providers in Illinois.

See all rheumatology providers in Illinois

Medicare billing

Part B allowed, 2024
$520,719
Medicare patients
363
Services billed
72,362

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab85$731,907
Enbrel SureclickEtanercept76$693,347
EnbrelEtanercept24$164,841
RinvoqUpadacitinib21$137,015
Cosentyx Sensoready PenSecukinumab15$113,525
Orencia ClickjectAbatacept16$106,171
KevzaraSarilumab14$62,367
MethotrexateMethotrexate Sodium412$11,540
Hydroxychloroquine Sulfate267$9,205
Leflunomide108$5,612
Prednisone497$4,093
Mycophenolate Mofetil14$2,667
Colchicine31$2,536
Sulfasalazine77$2,152
Allopurinol159$1,744

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$429$164,84124 claims
AbbVieRinvoq$442$137,01521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 287 rheumatology providers in Illinois.

Other rheumatology in Elmhurst

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →